Imugene (ASX:IMU) the first Australian patient has been dosed in the phase 1b clinical trial of its CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital in Sydney, according to a Friday filing with the Australian bourse.
The trial assesses the safety, tolerability, and clinical activity of azer-cel in patients with relapsed or refractory diffuse large B-cell lymphoma, a form of non-Hodgkin's lymphoma, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.